1-9 of 9
Lisa Musick
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

Lihua E. Budde, Adam J. Olszewski, Bei Hu, Nikesh Shah, Connie Lee Batlevi, Shen Yin, Iris To, Michael C. Wei, Martine Kallemeijn, Victor Orellana-Noia, Lisa Musick, Natasha Shamas, Navdeep Pal, Ashwini Shewade, Jason R. Westin
Journal: Blood
Blood (2024) 144 (Supplement 1): 2373.
https://doi.org/10.1182/blood-2024-194340
Published: 2024
Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew K. McMillan, Muhit Özcan, Violaine Safar, Gilles Salles, Jamie Hirata, Annie Yang, Lisa Musick, Matthew J. Matasar
Journal: Blood
Blood (2022) 140 (Supplement 1): 9464–9467.
https://doi.org/10.1182/blood-2022-157679
Published: 2022
Journal Articles

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Catherine S. Diefenbach, Brad S. Kahl, Lalita Banerjee, Andrew K. McMillan, Fiona Miall, Javier Briones, Raul Cordoba, John M. Burke, Jamie Hirata, Sunil Sharma, Lisa Musick, Pau Abrisqueta Costa
Journal: Blood
Blood (2022) 140 (Supplement 1): 2286–2288.
https://doi.org/10.1182/blood-2022-157720
Published: 2022
Journal Articles

POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew J. Matasar, Corinne Haioun, Juan-Manuel Sancho, Andreas Viardot, Jamie Hirata, Thomas Perretti, Lisa Musick, Andrew K McMillan
Journal: Blood
Blood (2021) 138 (Supplement 1): 3568.
https://doi.org/10.1182/blood-2021-145857
Published: 2021
Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Laurie H. Sehn, MDMPH, Mark Hertzberg, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Alex F. Herrera, MD, Sarit E Assouline, MD MSc, Christopher Flowers, MDMS, Tae Min Kim, MD PhD, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, MD PhD, Lisa Musick, Jamie Hirata, YiMeng Chang, Grace Ku, Matthew J Matasar, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–19.
https://doi.org/10.1182/blood-2020-137078
Published: 2020
Journal Articles

Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA

Alex F. Herrera, MD, Samuel Tracy, Brandon Croft, Stephen Opat, FRACP, FRCPA, MBBS, Jill Ray, Lisa Musick, Joseph N. Paulson, Laurie H. Sehn, MDMPH, Yanwen Jiang
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–25.
https://doi.org/10.1182/blood-2020-136645
Published: 2020
Journal Articles

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Giuseppe Gritti, MD PhD, Paula Marlton, MBBS FRACP FRCPA, Tycel J. Phillips, MD, Christopher Arthur, Rajat Bannerji, MDPhD, Paolo Corradini, Anna Johnston, John F. Seymour, Sam Yuen, MBBS, FRACP, FRCPA, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-136361
Published: 2020
Journal Articles

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

Catherine Diefenbach, MD, Brad S. Kahl, MD, Lalita Banerjee, FRCPath, Andrew K McMillan, FRCP, Fiona Miall, MD FRCPath, MRCP, BMBS, Javier Briones, MD PhD, Raul Cordoba, MD PhD, Jamie Hirata, PharmD, YiMeng Chang, MSc, Lisa Musick, PharmD, Pau Abrisqueta, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 126.
https://doi.org/10.1182/blood-2019-123669
Published: 2019
Journal Articles

An Interim Evaluation of Systemic F-Ara-a Exposure in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients Using An Optimal Sampling Design

Janel R Long-Boyle, PharmD, PhD, Shirley Yan, BS, Christopher C. Dvorak, MD, Biljana N. Horn, MD, Morton Jerome Cowan, MD, Liusheng Huang, PhD, Nancy Sambol, PharmD, Lisa Musick, PharmD, Francesca Aweeka, PharmD
Journal: Blood
Blood (2011) 118 (21): 1962.
https://doi.org/10.1182/blood.V118.21.1962.1962
Published: 2011